Drugs / umbilical cord-derived mesenchymal stromal cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04325594 | Mar 2020 → Jan 2023 | dilated cardiomyopathy, heart failure | The Research-Clinical Center for Cardiac Surgery and Transplantology LLP | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06145035 | Mar 2024 → Jan 2028 expected | myocardial ischemia | Roberto Bolli | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | umbilical cord-derived mesenchymal stromal cells | “allogeneic umbilical cord-derived mesenchymal stromal cells (MSCs)” NCT04325594 ↗ |
| Known as | UC MSCs | “umbilical cord-derived mesenchymal stromal cells (UC-MSCs)” NCT06145035 ↗ |
| Modality | Cell therapy | “umbilical cord-derived mesenchymal stromal cells (MSCs)” NCT04325594 ↗ |
| Route | Other | “intracoronary infusion” NCT04325594 ↗ |